Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 26, 2024
Daily News
September 26, 2024
- Kisunla Subject to Prior Pricing Review as It Follows Leqembi’s Footsteps
September 26, 2024
- Meiji’s COVID Jab Might Miss Initial Plan, but Awaits Real Game Next Year
September 26, 2024
- J&J to Offer Rybrevant for Free until NHI Price Listing
September 26, 2024
- Off-Year Debate “Won’t Progress” without Industry’s Behavioral Change: JMA Rep
September 26, 2024
- KOL Calls for Public Support for Truvada’s PrEP Use against HIV
September 26, 2024
- MHLW Panel Puts a Hold on Proposed Use of Abortion Pill at Clinics Without Beds
September 26, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…